For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
7
views
40
references
 Top references
cited by
49
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      282
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      HLSC-Derived Extracellular Vesicles Attenuate Liver Fibrosis and Inflammation in a Murine Model of Non-alcoholic Steatohepatitis

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Extracellular vesicles (EVs) are membrane vesicles released virtually by all cell types. Several studies have shown that stem cell-derived EVs may mimic both in vitro and in vivo the biological effects of the cells. We recently demonstrated that non-alcoholic steatohepatitis (NASH) is inhibited by treatment with human liver stem cells (HLSCs). The aim of the present study was to evaluate whether EVs released by HLSCs influence the progression of NASH, induced by a diet deprived of methionine and choline, in immunocompromised mice. EV treatment was initiated after 2 weeks of diet with a biweekly administration of three different doses. Bio-distribution evaluated by optical imaging showed a preferential accumulation in normal and, in particular, in fibrotic liver. EV treatment significantly improved liver function and reduced signs of liver fibrosis and inflammation at both morphological and molecular levels. In particular, we observed that, out of 29 fibrosis-associated genes upregulated in NASH liver, 28 were significantly downregulated by EV treatment. In conclusion, HLSC-derived EVs display anti-fibrotic and anti-inflammatory effects in a model of chronic liver disease, leading to an improvement of liver function.

          Abstract

          Stem cell-derived extracellular vesicles, by modulating pro-fibrotic and pro-inflammatory genes, improve liver function and morphology in an experimental murine model of non-alcoholic steatohepatitis.

          Related collections

          Most cited references40

          • Record: found
          • Abstract: found
          • Article: not found

          NIH Image to ImageJ: 25 years of image analysis

          Kevin W Eliceiri, Caroline A Schneider, Wayne S Rasband (2018)
          For the past twenty five years the NIH family of imaging software, NIH Image and ImageJ have been pioneers as open tools for scientific image analysis. We discuss the origins, challenges and solutions of these two programs, and how their history can serve to advise and inform other software projects.
          Article 0 comments Cited 8460 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Enrichr: a comprehensive gene set enrichment analysis web server 2016 update

            Maxim Kuleshov, Matthew Jones, Andrew D. Rouillard … (2016)
            Enrichment analysis is a popular method for analyzing gene sets generated by genome-wide experiments. Here we present a significant update to one of the tools in this domain called Enrichr. Enrichr currently contains a large collection of diverse gene set libraries available for analysis and download. In total, Enrichr currently contains 180 184 annotated gene sets from 102 gene set libraries. New features have been added to Enrichr including the ability to submit fuzzy sets, upload BED files, improved application programming interface and visualization of the results as clustergrams. Overall, Enrichr is a comprehensive resource for curated gene sets and a search engine that accumulates biological knowledge for further biological discoveries. Enrichr is freely available at: http://amp.pharm.mssm.edu/Enrichr.
            Article 0 comments Cited 2882 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.

              Zobair Younossi, Aaron Koenig, Dinan Abdelatif … (2016)
              Nonalcoholic fatty liver disease (NAFLD) is a major cause of liver disease worldwide. We estimated the global prevalence, incidence, progression, and outcomes of NAFLD and nonalcoholic steatohepatitis (NASH). PubMed/MEDLINE were searched from 1989 to 2015 for terms involving epidemiology and progression of NAFLD. Exclusions included selected groups (studies that exclusively enrolled morbidly obese or diabetics or pediatric) and no data on alcohol consumption or other liver diseases. Incidence of hepatocellular carcinoma (HCC), cirrhosis, overall mortality, and liver-related mortality were determined. NASH required histological diagnosis. All studies were reviewed by three independent investigators. Analysis was stratified by region, diagnostic technique, biopsy indication, and study population. We used random-effects models to provide point estimates (95% confidence interval [CI]) of prevalence, incidence, mortality and incidence rate ratios, and metaregression with subgroup analysis to account for heterogeneity. Of 729 studies, 86 were included with a sample size of 8,515,431 from 22 countries. Global prevalence of NAFLD is 25.24% (95% CI: 22.10-28.65) with highest prevalence in the Middle East and South America and lowest in Africa. Metabolic comorbidities associated with NAFLD included obesity (51.34%; 95% CI: 41.38-61.20), type 2 diabetes (22.51%; 95% CI: 17.92-27.89), hyperlipidemia (69.16%; 95% CI: 49.91-83.46%), hypertension (39.34%; 95% CI: 33.15-45.88), and metabolic syndrome (42.54%; 95% CI: 30.06-56.05). Fibrosis progression proportion, and mean annual rate of progression in NASH were 40.76% (95% CI: 34.69-47.13) and 0.09 (95% CI: 0.06-0.12). HCC incidence among NAFLD patients was 0.44 per 1,000 person-years (range, 0.29-0.66). Liver-specific mortality and overall mortality among NAFLD and NASH were 0.77 per 1,000 (range, 0.33-1.77) and 11.77 per 1,000 person-years (range, 7.10-19.53) and 15.44 per 1,000 (range, 11.72-20.34) and 25.56 per 1,000 person-years (range, 6.29-103.80). Incidence risk ratios for liver-specific and overall mortality for NAFLD were 1.94 (range, 1.28-2.92) and 1.05 (range, 0.70-1.56).
              Article 0 comments Cited 2852 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Contributors
                Giovanni Camussi
                Journal
                Journal ID (nlm-ta): Mol Ther
                Journal ID (iso-abbrev): Mol. Ther
                Title: Molecular Therapy
                Publisher: American Society of Gene & Cell Therapy
                ISSN (Print): 1525-0016
                ISSN (Electronic): 1525-0024
                Publication date (Print): 05 February 2020
                Publication date (Electronic): 28 October 2019
                Volume: 28
                Issue: 2
                Pages: 479-489
                Affiliations
                [1 ]Department of Medical Sciences, University of Torino, Torino, Italy
                [2 ]Molecular Biotechnology Centre, University of Torino, Torino, Italy
                [3 ]2i3T Società per la Gestione dell’Incubatore di Imprese e per il Trasferimento Tecnologico Scarl, University of Torino, Torino, Italy
                [4 ]Unicyte Srl, Torino, Italy
                Author notes
                [∗ ]Corresponding author: Giovanni Camussi, Department of Medical Sciences, University of Torino, Corso Dogliotti 14, 10126 Torino, Italy. giovanni.camussi@ 123456unito.it
                Article
                Publisher ID: S1525-0016(19)30470-8
                DOI: 10.1016/j.ymthe.2019.10.016
                PMC ID: 7001005
                PubMed ID: 31757759
                SO-VID: 6602f2f1-b24c-4c5e-b4d6-a268467ab2fd
                Copyright © © 2019 The Authors
                License:

                This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

                History
                Date received : 12 August 2019
                Date accepted : 22 October 2019
                Categories
                Subject: Original Article

                ScienceOpen disciplines: Molecular medicine
                Keywords: human liver stem cells,chronic liver disease,nash,nafld,methionine and choline deprived diet,stem cell-derived evs
                Data availability:
                ScienceOpen disciplines: Molecular medicine
                Keywords: human liver stem cells, chronic liver disease, nash, nafld, methionine and choline deprived diet, stem cell-derived evs

                Comments

                Comment on this article

                scite_

                Similar content282

                See all similar

                Cited by49

                See all cited by

                Most referenced authors637

                See all reference authors